BH3 mimetics induce apoptosis independent of DRP-1 in melanoma

[1]  S. Cory,et al.  The BCL-2 arbiters of apoptosis and their growing role as cancer targets. , 2018 .

[2]  Elizabeth J. Osterlund,et al.  BCL-2 family proteins: changing partners in the dance towards death. , 2018 .

[3]  J. Montero,et al.  Why do BCL-2 inhibitors work and where should we use them in the clinic? , 2017, Cell Death and Differentiation.

[4]  H. Clevers,et al.  Cancer stem cells revisited , 2017, Nature Medicine.

[5]  J. Visvader,et al.  Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer , 2017, Science Translational Medicine.

[6]  M. Butterworth,et al.  DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis , 2017, Cell Death & Disease.

[7]  A. Hadji,et al.  Killing Two Cells with One Stone: Pharmacologic BCL-2 Family Targeting for Cancer Cell Death and Immune Modulation , 2016, Front. Pediatr..

[8]  S. Robinson,et al.  Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments , 2016, Oncotarget.

[9]  A. Strasser,et al.  The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models , 2016, Nature.

[10]  Xu Luo,et al.  Bax/Bak activation in the absence of Bid, Bim, Puma, and p53 , 2016, Cell Death and Disease.

[11]  J. Wolchok,et al.  Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. , 2016, JAMA.

[12]  S. Robinson,et al.  Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells , 2016, Oncotarget.

[13]  T. Fehr,et al.  Distinctive Expression of Bcl-2 Factors in Regulatory T Cells Determines a Pharmacological Target to Induce Immunological Tolerance , 2016, Front. Immunol..

[14]  Asher Mullard.  Pioneering apoptosis-targeted cancer drug poised for FDA approval , 2016, Nature Reviews Drug Discovery.

[15]  Yu Shyr,et al.  Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy , 2016, Nature Communications.

[16]  H. Harada,et al.  Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer , 2016, Cancer biology & therapy.

[17]  P. Pinton,et al.  Mcl-1 involvement in mitochondrial dynamics is associated with apoptotic cell death , 2016, Molecular biology of the cell.

[18]  N. Sharpless,et al.  Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice , 2015, Nature Medicine.

[19]  A. Tolcher,et al.  Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors , 2015, Cancer Chemotherapy and Pharmacology.

[20]  James J. Hsieh,et al.  An Interconnected Hierarchical Model of Cell Death Regulation by the BCL-2 Family , 2015, Nature Cell Biology.

[21]  John Calvin Reed,et al.  Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia. , 2015, Blood.

[22]  Julie C. Sung,et al.  Activation of the Mitochondrial Fragmentation Protein DRP1 Correlates with BRAFV600E Melanoma , 2015, The Journal of investigative dermatology.

[23]  Xin Lu,et al.  MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor , 2015, Molecular Cancer Therapeutics.

[24]  M. Fujita,et al.  Understanding melanoma stem cells. , 2015, Melanoma management.

[25]  A. Strasser,et al.  The BCL-2 protein family, BH3-mimetics and cancer therapy , 2015, Cell Death and Differentiation.

[26]  N. Mukherjee,et al.  Alternative treatments for melanoma: targeting BCL-2 family members to de-bulk and kill cancer stem cells , 2015, Journal of Investigative Dermatology.

[27]  S. Ramaswamy,et al.  Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer , 2015, Proceedings of the National Academy of Sciences.

[28]  J. Chipuk,et al.  Mitochondrial division is requisite to RAS-induced transformation and targeted by oncogenic MAPK pathway inhibitors. , 2015, Molecular cell.

[29]  L. Lam,et al.  Antihelminthic benzimidazoles potentiate navitoclax (ABT-263) activity by inducing Noxa-dependent apoptosis in non-small cell lung cancer (NSCLC) cell lines , 2015, Cancer Cell International.

[30]  M. Cragg,et al.  Role of the pro-survival molecule Bfl-1 in melanoma. , 2015, The international journal of biochemistry & cell biology.

[31]  William A. Flavahan,et al.  Mitochondrial Control by DRP1 in Brain Tumor Initiating Cells , 2015, Nature Neuroscience.

[32]  C. Tse,et al.  Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax) , 2015, Cell Death and Disease.

[33]  S. Robinson,et al.  Combining a BCL2 Inhibitor with the Retinoid Derivative Fenretinide Targets Melanoma Cells Including Melanoma Initiating Cells , 2014, The Journal of investigative dermatology.

[34]  J. Schlom,et al.  Abstract 628: Pan-Bcl-2 inhibitor, GX15-070 (Obatoclax), decreases human T regulatory lymphocytes while preserving effector T Lymphocytes: A rationale for its use in combination immunotherapy , 2014 .

[35]  M. Biffoni,et al.  Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer , 2014, Cell Death and Differentiation.

[36]  N. Haass,et al.  Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy , 2014, Pigment cell & melanoma research.

[37]  R. Sullivan,et al.  Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics , 2014, PloS one.

[38]  H. Sesaki,et al.  Drp1 is dispensable for apoptotic cytochrome c release in primed MCF10A and fibroblast cells but affects Bcl‐2 antagonist‐induced respiratory changes , 2014, British journal of pharmacology.

[39]  N. Tanaka,et al.  Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer , 2014, Cell Death and Disease.

[40]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[41]  Peter E. Czabotar,et al.  Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy , 2013, Nature Reviews Molecular Cell Biology.

[42]  A. Letai,et al.  Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis , 2013, Apoptosis.

[43]  J. Armstrong,et al.  Oncogenic BRAF signalling increases Mcl‐1 expression in cutaneous metastatic melanoma , 2013, Experimental dermatology.

[44]  C. Blanpain,et al.  Unravelling cancer stem cell potential , 2013, Nature Reviews Cancer.

[45]  S. Fulda.  Regulation of apoptosis pathways in cancer stem cells. , 2013, Cancer letters.

[46]  L. Sommer,et al.  Testing the cancer stem cell hypothesis in melanoma: the clinics will tell. , 2013, Cancer letters.

[47]  John M. Ashton,et al.  BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. , 2013, Cell stem cell.

[48]  Jessica M. Rusert,et al.  A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. , 2013, Cell stem cell.

[49]  Jun S. Song,et al.  BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition , 2013, Proceedings of the National Academy of Sciences.

[50]  P. Hersey,et al.  The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance. , 2013, Carcinogenesis.

[51]  B. Stecca,et al.  Culture and isolation of melanoma-initiating cells. , 2013, Current protocols in stem cell biology.

[52]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[53]  M. McCarter,et al.  ALDH1A Isozymes are Markers of Human Melanoma Stem Cells and Potential Therapeutic Targets , 2012, Stem cells.

[54]  N. Pimpinelli,et al.  HEDGEHOG‐GLI Signaling Drives Self‐Renewal and Tumorigenicity of Human Melanoma‐Initiating Cells , 2012, Stem cells.

[55]  G. Giaccone,et al.  Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[56]  D. Cooper,et al.  The Combination of BH3-Mimetic ABT-737 with the Alkylating Agent Temozolomide Induces Strong Synergistic Killing of Melanoma Cells Independent of p53 , 2011, PloS one.

[57]  D. Andrews,et al.  BH3-only proteins: Orchestrators of apoptosis. , 2011, Biochimica et biophysica acta.

[58]  J. Schlom,et al.  Effect of a small molecule BCL‐2 inhibitor on immune function and use with a recombinant vaccine , 2010, International journal of cancer.

[59]  Irving L. Weissman,et al.  Human Melanoma Initiating Cells Express Neural Crest Nerve Growth Factor Receptor CD271 , 2010, Nature.

[60]  M. Frank,et al.  The therapeutic promise of the cancer stem cell concept. , 2010, The Journal of clinical investigation.

[61]  A. Aplin,et al.  Mcl-1 Is Required for Melanoma Cell Resistance to Anoikis , 2009, Molecular Cancer Research.

[62]  C. Akgul.  Mcl-1 is a potential therapeutic target in multiple types of cancer , 2009, Cellular and Molecular Life Sciences.

[63]  J. Visvader,et al.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.

[64]  B. Li,et al.  Inducing apoptosis and enhancing chemosensitivity to Gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell , 2008, Cancer Chemotherapy and Pharmacology.

[65]  T. Kuwana,et al.  Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization. , 2008, Developmental cell.

[66]  W. Xie,et al.  Noxa/Mcl-1 balance regulates susceptibility of cells to camptothecin-induced apoptosis. , 2007, Neoplasia.

[67]  Irving L Weissman,et al.  Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. , 2006, Cancer research.

[68]  N. Ahn,et al.  RhoC promotes human melanoma invasion in a PI3K/Akt-dependent pathway. , 2006, The Journal of investigative dermatology.

[69]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[70]  G. de Murcia,et al.  Importance of Poly(ADP-ribose) Polymerase and Its Cleavage in Apoptosis , 1998, The Journal of Biological Chemistry.

[71]  A. Letai,et al.  UvA-DARE ( Digital Academic Repository ) Targeting cancer stem cells : Modulating apoptosis and stemness Çolak , 2016 .

[72]  J. Opferman,et al.  Delving deeper: MCL-1's contributions to normal and cancer biology. , 2013, Trends in cell biology.

[73]  D. Galloway,et al.  Generation of a human melanocyte cell line by introduction of HPV16 E6 and E7 genes , 1997, In Vitro Cellular & Developmental Biology - Animal.